Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2020-12-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于与北京大学第三医院签订科研合作协议的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about signing a scientific research cooperation agreement with a hospital. It details the agreement's terms, cooperation content, financial commitments, and potential impacts on the company. There are no financial statements, quarterly or annual results, or audit information. The document is relatively short (3025 characters) and serves as a formal announcement of a corporate agreement rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a voting result, director dealing, or capital change announcement. The content is about a strategic cooperation agreement and its implications, which is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2020-12-07 Chinese
关于控股股东完成债权转股权涉及权益变动过户登记暨相关股权解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of equity changes related to debt-to-equity conversion by the controlling shareholder, including share transfer registration and pledge release details. It contains specific shareholding changes, pledge status, and dates of these events. There is no financial statement, earnings data, or management discussion. The document is a formal disclosure of shareholding and pledge status changes due to debt restructuring, which fits the category of Major Shareholding Notification (MRQ). The document length is 2517 characters, which is typical for such announcements. Therefore, the classification is MRQ with high confidence.
2020-12-04 Chinese
关于控股股东股票质押式回购交易调整购回交易日和部分股权解除质押及再质押的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the adjustment of stock pledge repurchase transactions by the controlling shareholder, including changes in pledge dates, partial release of pledged shares, and re-pledging activities. It contains specific data on shareholding, pledge ratios, financing purposes, and risk assessments related to the controlling shareholder's stock pledges. There is no indication that this is a full financial report, earnings release, or management discussion. The content focuses on share pledge transactions and related financing activities by the controlling shareholder. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to the specificity and nature of the content.
2020-12-03 Chinese
北京国枫律师事务所关于中源协和细胞基因工程股份有限公司2020年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and results of a company's 2020 second extraordinary general meeting of shareholders. It details the legality and validity of the meeting's notice, attendance, voting procedures, and resolutions passed. It does not contain financial statements or financial performance data, nor is it a transcript or presentation. It is a legal opinion related to a shareholders' meeting, specifically about the voting results and procedural compliance. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3119 characters, which is consistent with a detailed legal opinion rather than a full report or announcement of a report publication.
2020-11-16 Chinese
2020年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2020 second extraordinary general meeting of shareholders of the company. It includes information about the meeting date, location, attendance, voting results on various proposals, and legal witness statements. The content focuses on the voting outcomes and procedural compliance rather than presenting a full report or financial statements. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is relatively short (2098 characters), but it contains substantive voting results, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is DVA with high confidence.
2020-11-16 Chinese
细胞基因工程股份有限公司关于召开2020年第二次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2020 second extraordinary general meeting of shareholders for the company 中源协和细胞基因工程股份有限公司. It includes information about the meeting date, voting methods (including online voting), meeting agenda items, voting procedures, registration methods, and other logistical details. It also includes an authorization letter template for proxy voting. The document does not contain any financial statements, audit reports, or results of the meeting. It is a notice or announcement related to a shareholders' meeting rather than the meeting materials or results themselves. Given the content and length (3377 characters), it fits the category of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2020-11-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.